Paolo Ascenzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paolo Ascenzi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Martino Bolognesi
Department of Biosciences, University of Milan, Milan, Italy
16 shared publications Alessio Bocedi
National Institute for Infectious Diseases IRCCS ‘Lazzaro Spallanzani’, Rome, Italy
9 shared publications- Massimo Coletta
IRCCS Fondazione Bietti, Roma, Italy
7 shared publications - Mauro Fasano
Department of Science and High Technology, University of Insubria, 22100 Como, Italy
7 shared publications Luigi Gradoni
Laboratorio di Parassitologia, Istituto Superiore di Sanità, Viale Regina Elena 299, I-00161 Rome, Italy
6 shared publications- Paolo Visca
Department of Science, Roma Tre University, 00146 Rome, Italy
6 shared publications
Latest Publications
- Open Access
- 20 December 2011
- Published by Wiley in IUBMB Life
- Vol. 63 (12) , 1116
Drug binding to sudlow's site i impairs allosterically human serum heme-albumin-catalyzed peroxynitrite detoxification, iubmb life 2010 oct;62(10):776-80
- 20 December 2011
- Published by Wiley in IUBMB Life
- Vol. 63 (12) , 1116
Open AccessDrug binding to sudlow's site i impairs allosterically human serum heme-albumin-catalyzed peroxynitrite detoxification, iubmb life 2010 oct;62(10):776-80
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 558a
Archaeal Protoglobin Structures: Novel Ligand Diffusion Paths And Heme Reactivity Modulation
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 558a
Archaeal Protoglobin Structures: Novel Ligand Diffusion Paths And Heme Reactivity Modulation
- 1 December 2008
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 15 (30) , 3280
Erratum-II
- 1 December 2008
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 15 (30) , 3280
Erratum-II
- 1 November 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 363 (4) , 931-936
Peroxynitrite-mediated oxidation of ferrous carbonylated myoglobin is limited by carbon monoxide dissociation
- 1 November 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 363 (4) , 931-936
Peroxynitrite-mediated oxidation of ferrous carbonylated myoglobin is limited by carbon monoxide dissociation
- 6 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 359 (4) , 871-876
Ferricyanide-mediated oxidation of ferrous nitrosylated sperm whale myoglobin involves the formation of the ferric nitrosylated intermediate
- 6 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 359 (4) , 871-876
Ferricyanide-mediated oxidation of ferrous nitrosylated sperm whale myoglobin involves the formation of the ferric nitrosylated intermediate
- 1 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (3) , 809-814
NO dissociation represents the rate limiting step for O2-mediated oxidation of ferrous nitrosylated Mycobacterium leprae truncated hemoglobin O
- 1 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (3) , 809-814
NO dissociation represents the rate limiting step for O2-mediated oxidation of ferrous nitrosylated Mycobacterium leprae truncated hemoglobin O
- Open Access
- 22 December 2006
- Published by Wiley in The FEBS Journal
- Vol. 274 (2) , 551-562
Reductive nitrosylation and peroxynitrite‐mediated oxidation of heme–hemopexin
Hemopexin (HPX), which serves as a scavenger and transporter of toxic plasma heme, has been postulated to play a key role in the homeostasis of NO. In fact, HPX–heme(II) reversibly binds NO and facilitates NO scavenging by O2. HPX–heme is formed by two four‐bladed β‐propeller domains. The heme is bound between the two β‐propeller domains, residues His213 and His266 coordinate the heme iron atom. HPX–heme displays structural features of heme‐proteins endowed with (pseudo‐)enzymatic activities. In this study, the kinetics of rabbit HPX–heme(III) reductive nitrosylation and peroxynitrite‐mediated oxidation of HPX–heme(II)–NO are reported. In the presence of excess NO, HPX–heme(III) is converted to HPX–heme(II)–NO by reductive nitrosylation. The second‐order rate constant for HPX–heme(III) reductive nitrosylation is (1.3 ± 0.1) × 101 m−1·s−1, at pH 7.0 and 10.0 °C. NO binding to HPX–heme(III) is rate limiting. In the absence and presence of CO2 (1.2 × 10−3 m), excess peroxynitrite reacts with HPX–heme(II)–NO (2.6 × 10−6 m) leading to HPX–heme(III) and NO, via the transient HPX–heme(III)–NO species. Values of the second‐order rate constant for HPX–heme(III)–NO formation are (8.6 ± 0.8) × 104 and (1.2 ± 0.2) × 106 m−1·s−1 in the absence and presence of CO2, respectively, at pH 7.0 and 10.0 °C. The CO2‐independent value of the first‐order rate constant for HPX–heme(III)–NO denitrosylation is (4.3 ± 0.4) × 10−1 s−1, at pH 7.0 and 10.0 °C. HPX–heme(III)–NO denitrosylation is rate limiting. HPX–heme(II)–NO appears to act as an efficient scavenger of peroxynitrite and of strong oxidants and nitrating species following the reaction of peroxynitrite with CO2 (e.g. ONOOC(O)O–, CO3–, and NO2).
- 22 December 2006
- Published by Wiley in The FEBS Journal
- Vol. 274 (2) , 551-562
Open AccessReductive nitrosylation and peroxynitrite‐mediated oxidation of heme–hemopexin
Hemopexin (HPX), which serves as a scavenger and transporter of toxic plasma heme, has been postulated to play a key role in the homeostasis of NO. In fact, HPX–heme(II) reversibly binds NO and facilitates NO scavenging by O2. HPX–heme is formed by two four‐bladed β‐propeller domains. The heme is bound between the two β‐propeller domains, residues His213 and His266 coordinate the heme iron atom. HPX–heme displays structural features of heme‐proteins endowed with (pseudo‐)enzymatic activities. In this study, the kinetics of rabbit HPX–heme(III) reductive nitrosylation and peroxynitrite‐mediated oxidation of HPX–heme(II)–NO are reported. In the presence of excess NO, HPX–heme(III) is converted to HPX–heme(II)–NO by reductive nitrosylation. The second‐order rate constant for HPX–heme(III) reductive nitrosylation is (1.3 ± 0.1) × 101 m−1·s−1, at pH 7.0 and 10.0 °C. NO binding to HPX–heme(III) is rate limiting. In the absence and presence of CO2 (1.2 × 10−3 m), excess peroxynitrite reacts with HPX–heme(II)–NO (2.6 × 10−6 m) leading to HPX–heme(III) and NO, via the transient HPX–heme(III)–NO species. Values of the second‐order rate constant for HPX–heme(III)–NO formation are (8.6 ± 0.8) × 104 and (1.2 ± 0.2) × 106 m−1·s−1 in the absence and presence of CO2, respectively, at pH 7.0 and 10.0 °C. The CO2‐independent value of the first‐order rate constant for HPX–heme(III)–NO denitrosylation is (4.3 ± 0.4) × 10−1 s−1, at pH 7.0 and 10.0 °C. HPX–heme(III)–NO denitrosylation is rate limiting. HPX–heme(II)–NO appears to act as an efficient scavenger of peroxynitrite and of strong oxidants and nitrating species following the reaction of peroxynitrite with CO2 (e.g. ONOOC(O)O–, CO3–, and NO2).
- 1 December 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 351 (2) , 528-533
Peroxynitrite scavenging by ferrous truncated hemoglobin GlbO from Mycobacterium leprae
- 1 December 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 351 (2) , 528-533
Peroxynitrite scavenging by ferrous truncated hemoglobin GlbO from Mycobacterium leprae
- 1 January 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 339 (1) , 450-456
Nitric oxide scavenging by Mycobacterium leprae GlbO involves the formation of the ferric heme-bound peroxynitrite intermediate
- 1 January 2006
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 339 (1) , 450-456
Nitric oxide scavenging by Mycobacterium leprae GlbO involves the formation of the ferric heme-bound peroxynitrite intermediate
- Open Access
- 6 December 2005
- Published by Wiley in The FEBS Journal
- Vol. 272 (24) , 6287-6296
Allosteric modulation of anti‐HIV drug and ferric heme binding to human serum albumin
Human serum albumin (HSA), the most prominent protein in plasma, is best known for its exceptional capacity to bind ligands (e.g. heme and drugs). Here, binding of the anti‐HIV drugs abacavir, atazanavir, didanosine, efavirenz, emtricitabine, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, stavudine, and zidovudine to HSA and ferric heme–HSA is reported. Ferric heme binding to HSA in the absence and presence of anti‐HIV drugs was also investigated. The association equilibrium constant and second‐order rate constant for the binding of anti‐HIV drugs to Sudlow's site I of ferric heme–HSA are lower by one order of magnitude than those for the binding of anti‐HIV drugs to HSA. Accordingly, the association equilibrium constant and the second‐order rate constant for heme binding to HSA are decreased by one order of magnitude in the presence of anti‐HIV drugs. In contrast, the first‐order rate constant for ligand dissociation from HSA is insensitive to anti‐HIV drugs and ferric heme. These findings represent clear‐cut evidence for the allosteric inhibition of anti‐HIV drug binding to HSA by the heme. In turn, anti‐HIV drugs allosterically impair heme binding to HSA. Therefore, Sudlow's site I and the heme cleft must be functionally linked.
- 6 December 2005
- Published by Wiley in The FEBS Journal
- Vol. 272 (24) , 6287-6296
Open AccessAllosteric modulation of anti‐HIV drug and ferric heme binding to human serum albumin
Human serum albumin (HSA), the most prominent protein in plasma, is best known for its exceptional capacity to bind ligands (e.g. heme and drugs). Here, binding of the anti‐HIV drugs abacavir, atazanavir, didanosine, efavirenz, emtricitabine, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, stavudine, and zidovudine to HSA and ferric heme–HSA is reported. Ferric heme binding to HSA in the absence and presence of anti‐HIV drugs was also investigated. The association equilibrium constant and second‐order rate constant for the binding of anti‐HIV drugs to Sudlow's site I of ferric heme–HSA are lower by one order of magnitude than those for the binding of anti‐HIV drugs to HSA. Accordingly, the association equilibrium constant and the second‐order rate constant for heme binding to HSA are decreased by one order of magnitude in the presence of anti‐HIV drugs. In contrast, the first‐order rate constant for ligand dissociation from HSA is insensitive to anti‐HIV drugs and ferric heme. These findings represent clear‐cut evidence for the allosteric inhibition of anti‐HIV drug binding to HSA by the heme. In turn, anti‐HIV drugs allosterically impair heme binding to HSA. Therefore, Sudlow's site I and the heme cleft must be functionally linked.